Loading…
PHG
Koninklijke Philips NV
NYSE· Healthcare· Medical Devices· CUSIP 500472303
$26.92+2.63%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Koninklijke Philips NV (PHG) is listed on NYSE and classified in Medical Devices, part of the Healthcare sector. It is headquartered in Amsterdam, Netherlands and has 63,670 employees. The company is worth $26.31B and trades at 20.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was €17.83B in fiscal 2025, down 1.0% from the year before. Net income was €895M. The share price is 19.5% below its 52-week high of $33.44. It pays a dividend yielding 3.75%. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $4.21M. In that quarter, 3 of them reduced the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $26.31B
- P/E
- 20.1x
- Forward P/E
- 14.2x
- P/B
- 2.0x
- Dividend yield
- 3.75%
- Payout
- 75.37%
- EPS
- $1.34
- ROE
- 10.15%
- Profit margin
- 6.31%
- Revenue growth
- +0.50%
- Beta
- 0.92
- 52-week high
- $33.44
- 52-week low
- $23.62
History
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in EUR, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Ken GriffinReducedCitadel Advisors · Q2 2026$4.21M154.78K shares · 0.0% of portfolio- Cliff AsnessHeldAQR Capital Management · Q2 2026$3.55M130.71K shares · 0.0% of portfolio
- Steve CohenReducedPoint72 Asset Management · Q2 2026$2.37M87.03K shares · 0.0% of portfolio
- Israel EnglanderReducedMillennium Management · Q2 2026$454.37K16.71K shares · 0.0% of portfolio
Price over time
▼ -26.8% over 5Y.
today you would have $613.04▼ -38.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $27.08 | $25.32 | $23.33 | $14.99 | |
| EPS | €0.94 | -€0.75 | -€0.49 | -€1.68 | |
| Dividend yield | — | 3.57% | — | — | 6.43% |
| Profit margin | -3.23% | 5.02% | -3.90% | -2.56% | -9.02% |
| ROE | -4.86% | 8.17% | -5.85% | -3.87% | -12.14% |
This company reports in EUR, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by EUR, so they are not shown; EPS is in EUR. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$19.91
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$5.03
Earnings growing 0.0% a year plus a 3.8% dividend yield. Growth capped at 25%.
Earnings
$32.54
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
$33.99
Dividend growing 5.6% a year against a 8.6% required return, from the stock’s beta.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $19.16 (avg. of 3)+Dividends $33.99÷ 2 =$26.57
$26.57
4 methods answered, across 2 families.
$19.93
Room for errors in the reported numbers.
$26.92
-1.3% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LHLabcorp Holdings Inc | $329.93 | 27.3x | 3.1x | 0.87% | 11.73% | $26.76B |
| DGXQuest Diagnostics Inc | $243.28 | 25.8x | 3.6x | 1.41% | 14.60% | $26.85B |
| ROIVRoivant Sciences Ltd. | $37.45 | — | 6.4x | 0.00% | -8.52% | $27.05B |
| UTHRUNITED THERAPEUTICS Corp | $584.79 | 20.9x | 3.9x | 0.00% | 19.32% | $25.08B |
| WSTWest Pharmaceutical Services Inc | $394.03 | 50.5x | 9.3x | 0.22% | 19.09% | $27.73B |
| GMABGenmab A/s | $40.00 | 31.5x | 4.0x | 0.00% | 14.00% | $24.6B |
About the company
- 63,670
- Amsterdam, Netherlands